



Cancer Endometrium PO - Recent Insights

AROICON 2024 ICRO Preconference Workshop Interactive Modules for Problem-based Assessment and Case-based Teaching

Dr Manur Gururajachar Janaki. MS Ramaiah Medical College Ramaiah university of applied sciences 28th November 2024



My Team...









The objectives of the session...

- To know the recent changes in the understanding of endometrial cancer
- > To understand various molecular subtypes of EC
- > To know their clinical applications
- > To understand the limitations of molecular profiling for EC





What are new concepts in EC...

- ≻Pathology..
 - CGA looked into the transcriptional, proteomic and genomic aspects done on formalin fixed paraffin blocks
- ≻Staging 2023..
 - ➢In early stages, prefix of m
- ≻Surgery..
 - ➢ Lap/Robotic, SLND, Avoid LND, Fertility preservation
- ➢Radiation/systemic therapy..
 - ➢ Personalised



Changes in stage I

FIGO 2023



Stage I	Confined to the uterine corpus and ovary ^c
IA	Disease limited to the endometrium OR non-aggressive histological type, i.e. low-grade endometroid, with invasion of less than half of myometrium with no or focal lymphovascular space involvement (LVSI) OR good prognosis disease
	IA1 Non-aggressive histological type limited to an endometrial polyp OR confined to the endometrium
	IA2 Non-aggressive histological types involving less than half of the myometrium with no or focal LVSI
	IA3 Low-grade endometrioid carcinomas limited to the uterus and ovary ⁶
IB	Non-aggressive histological types with invasion of half or more of the myometrium, and with no or focal LVSI ^d
IC	Aggressive histological types [*] limited to a polyp or confined to the endometrium

- IA3-low grade, uterus and ovary (unilateral, limited to ovary and capsule intact, less than 5 LVSI)
- IC-aggressive histopathology, polyp/endometrium

Changes in stage II

Stage II	Invasion of cervical stroma without extrauterine extension OR with substantial LVSI OR aggressive histological types with myometrial invasion
IIA	Invasion of the cervical stroma of non-aggressive histological types
IIB	Substantial LVSI ^d of non-aggressive histological types
IIC	Aggressive histological types ^e with any myometrial involvement

- IIA -stroma/nonaggressive
- IIB-LVSI/non aggressive
- IC-aggressive with MI





<u>Clinico-pathology based Risk stratification...</u>

Low risk	Stage 1A (G1,2), endometrioid type No LVSI
Intermediate risk	Stage 1B (G1,2), endometrioid type No LVSI
High Intermediate risk	Stage IA G3 ±LVSI Stage IG1-2+ LVSI ±MI
High risk	Stage 1B (G3), endometrioid type ± LVSI Stage II, Stage III with no residual disease All stages non-endometrioid type or carcinosarcoma
Advanced	Stage III with presence of residual disease and stage IV A
Metastatic	Stage IV B





Cancer Genomic Atlas	Pole Mutation	MMR d, MSI-H	NSMP	P53abn
What is it?	Mutations in exonuclease domain of POLE gene	Copy number High	Copy number low	high somatic Copy- number alterations and mutation profiles
Mutation rate	232 X10 ⁻⁶ /Mb	18 X10 ⁻⁶ /Mb	2.9 X10 ⁻⁶ /Mb	2.3 X10 ⁻⁶ /Mb
Occurrence(PORTEC III)	12%	33%	32%	23%
Immunogenicity	Very high (ultramutated- pembrolizumab ?)	High/immune evasive tu cells	Nil	Nil
How detected?	NGS	IHC/PCR	IHC	IHC
Prognosis	Very good	variable	Intermediate, 50% endometrioid	Bad,mostly non endometrioid
Treatment	De-escalate? PORTEC-4A/Rainbo	Role for Immunotherapy?	Hormone sensitive	RTCT and adjuvant chemo
Outcome (5 yr RFS)	98%vs 73%	72%	74%	48%
Remarks	hypersensitivity to adjuvant therapy	More of LVSI	HT	Very aggressive





Indications for Molecular Testing...

- ➢All patients
 - ➢Risk stratification
 - Selection of adjuvant therapy

➢Specially grade III

- ➢Its an heterogenous group of cancers
- Differs with respect to prognosis/clinical/molecular
- Stage Im_{p53abn}..aggressive treatment results in better RFS p<0.001 as per PORTEC III



Shifts in staging with molecular analysis



TCGA Subgroup	Mutated Genes	Genetic Abberation	Surrogate Marker	Prevalence	Histology	FIGO Grade	Stage	Risk Group	Recurrence Status	Prognosis												
						Low (G1-2)	IA	Low risk	 LVSI (-) or focal 	25												
		Microsatellite					IB															
	MLH1, MSH2, MSH6, PMS2	instability, somatic	MSH6, PMS2 IHC expression	24.7% of G1-2 tumors	24.7% of G1-2			IA	Intermediate													
Iypermutated MSI/MSI-		or germline mutations in MMR genes and			EEC	EEC High (G3)	IB		Regardless of LVSI status	Variable												
H/MMRd	110110,11002	epigenetic changes				Rega	Regardless of	1	High- intermediate	Substanial LVSI	1000000000000000											
		(i.e., MSH1 silencing)		39.7% of G3		the grade	п	internicensie	(-)	· · · · · ·												
	_	Succession,		tumors		Link	III–IVA	LT als stale	No RD													
					Non-EEC *	High	I–IVA	- High risk	MI, no RD													
	TP53 wild type	Low number of mutations, microsatellite stability	Normal p53 IHC expression			Low	IA	Low risk Intermediate	LVSI (-) or focal													
Copy-number- low (CNL)/non specific				63.5% of G1-2 tumors			IB															
							IA															
				Normal p53 IHC expression	Normal p53 IHC expression	Normal p53 IHC expression	Normal p53 IHC expression)	EEC	EEC High	High	IB	- High-	Regardless of LVSI status					
molecular rofile (NSMP)				28% of G3 tumors	(7)	28% of G3	28% of G3	28% of G3	28% of G3	28% of G3	28% of G3	Regardless of	I	intermediate	Substanial LVSI							
						the grade High	the p	the grade	п	 Interaction of the state 	(-)											
							High	III–IVA	- High risk	No RD	<											
							1	Non-EEC *	mgn	I–IVA		ML no RD										
Copy-number- high (CNH)/p53abn		1P53 somatic expression or aneuploidy tumors	Non-EEC *	n.e.m.n.r.	IA	Intermediate	Without MI															
		TP53	P53 mutation with sim	with simultaneous		with simultaneous testing	with simultaneous testing	with simultaneous testing	n with simultaneous testing	25% of G3 EEC	EEC or non-EEC *	N/A	I–IVA	High	MI, no RD	Unfavorabl						
POLE ultramutated (POLEmut)	1	Somatic mutation of POLE, TP53		6.2% of G1-2 tumors	EEC or non-EEC *		. I–II		2010220	erre »												
		gene/molecular analysis 12.1% of G3 tumors		12.1% of G3	High (G3)	1-11	Low	No RD	Excellent													

Cancers 2022, 14, 4500. https://doi.org/10.3390/cancers14184500







≻65 yrs,P4L4,22 yrs postmenopausal bleed,HTN,5 kg weight loss

►U/S Hyperechoic solid lesion,34X25mm

MRI 19X35X30mm, hyperintense, thin myometrium

► Robotic TAHBSO

Serous carcinoma,pT1aN0M0,Her 2neu+++



Case 2



≻54 yrs, Ca Breast,pT4bN2M0,ER/PR+/Her2 –ve

➢Surgery-CT-RT-Letrozole

≻8 yrs later, Postmenopausal bleed, O/E mild yellowish discharge

►U/S 4.5X3.6X4.3cm, mild internal vascularity


▶ PET lesion uterus SUV 12

MRI fundus to internal os, RT ext iliac 0.9X1.7cm

➢ Pipelle aspirate poorly dif ca









Histomolecular Report...



- >6X3.8X3.5 cm, High Gr EC
 >MI <1/3rd
 >LVSI-ve, serosa-ve,para –ve
 >0/2 LNs
 >pT1aN0M0
- ≻MSI-High,
- ➢P53 Wild type
- ➢POLE not mutated







TEST NAME

MMR Panel

SPECIMEN INFORMATION

Received two paraffin blocks. Test performed on block no. 2728/24 (G)

CLINICAL HISTORY

Postmenopausal bleeding with thickened endometrium.

METHODOLOGY

Immunohistochemistry





DIAGNOSIS						
MARKERS	RESULT	IMAGE				
hMSH-6(EP-49)	INTACT NUCLEAR EXPRESSION					
hMSH-2(RED2)	INTACT NUCLEAR EXPRESSION					
hMLH-1(GM011)	INTACT NUCLEAR EXPRESSION					

MUTATION TYPE	GENES TESTED	RESULTS	
SNVs and short indels	TP53	Not detected	
SNVs and short indels	POLE	Not detected	





Adjuvant therapy based on subtypes

	CTRT (5yr PFS)	RT (5yr PFS)	P value
POLE mutation	100%	97%	0.637
P53abn	59%	36%	0.019
MMRd	68%	76%	0.428
NSMP	80%	68%	0.243
	5 yr OS	5yr OS	
MMRd	79%	84%	0.445
MMRd vs MMRp	adding RT improved DFS in	MMRd for Ib and II,gr3 EC	

Interpretation:

- Adding chemo helps pts with mutant p53
- Adding RT and not chemo helps MMRd
- > De-escalation possible in POLE mut
- HT helpful for NSMP





Limitations of molecular profiling

- > Non availability
- Only few mutations are known
- Lack of robust data for day to day use
- Results of PORTEC 4a/TAPER/TRANSPORTEC RAINBO yet to come
- Financial liability

Risk	Criteria	Adjuvant Therapy:
low	 IA, grade 1–2 endometrioid carcinoma No LVSI POLE-mutated tumors, regardless of other features 	 No adjuvant therapy is recommended. Excellent prognosis with surgery alone.
Intermediate	 I, grade 3 endometrioid carcinoma without LVSI IA, grade 3 with focal LVSI IB, grade 1–2 with no LVSI Exclusion: p53-abnormal tumors or MSI-high cases with aggressive features 	 Vaginal brachytherapy is preferred to reduce local recurrence. No systemic chemotherapy.
High- Intermediate	 I–II with substantial risk factors: MI (≥50%) Grade 3 endometrioid histology Substantial LVSI Age >60 years with additional risk features 	 Vaginal brachytherapy ± pelvic radiotherapy for local control. Systemic chemotherapy (e.g., carboplatin and paclitaxel) considered for higher risk patients, particularly those with p53-abnormal or NSMI tumors.
High Risk	 stage III–IVA endometrioid carcinoma Non-endometrioid histologies p53-abnormal tumors (any stage) extensive LVSI 	 Chemotherapy (carboplatin and paclitaxel) and external beam radiation therapy (EBRT). sequential or sandwich approaches to chemoradiotherapy. Hormone therapy may have a role for hormon receptor-positive tumors in selected cases.

OCIATION O

ABO CON 2024

nber 38° in Docer Venue: 73 6






Additional biomarkers for immunotherapy...

Homologous recombination deficiency (HRD scoring)
 More than 4 –poor survival
 Higher scores – increased response to Cis/Pacli/olaparib
 HER 2
 Similar to TP53,
 Immune markers
 PD L1,TIL











So, at the end...

- Endometrial cancers are a heterogenous group of cancers
- Molecular profiling could upstage/downstage the disease
- Complementary to clinic-pathological features
- Results of ongoing trials will help in either de-escalating or adjuvant therapy selection for EC
- Adjuvant radiation can be personalised to get maximum benefit.



Our Reference Literature from.....



ASTRO/ESTRO/ESMO/ACOG/BCOG/ ESP and ICMR

REVIEW ARTICLE Gynecology	Trontiers Frontiers in Medicine	TYPE Review Humanized DR January 2024 DOI 10.5389/hmed.2023.1244634
Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies	OPEN ACCESS COTEO NY Emanuelle Perrone, Agostino Germelli University Polyclinic	Recent management of endometrial cancer: a narrative review of the literature
NCCN Guidelines	UpToDate	

